[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cardiometabolic-syndrome\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cardiometabolic-syndrome":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,18,0,[8,52,80,107,131,154,173,196,217,244,266,296,310,328,356,390,426,452],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":32,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100053765","phase-4-ldl-c-optimization-using-inclisiran-in-patients-in-which-drug-drug-interactions-limit-ldl-lowering-100053765",false,"NCT06865885","LDL-C Optimization Using Inclisiran in Patients in Which Drug-Drug Interactions Limit LDL Lowering","Study of Optimal LDL-C Value Enhancement With Inclisiran in Patients With Multiple Comorbidities in Which There Are Drug-Drug Interactions Limiting LDL-C Lowering","SOLVE-LDL-C","Inclusion Criteria:\n\n* Provision of signed and dated informed consent form.\n* Stated willingness to comply with all study procedures and availability for the duration of the study, including potential randomization to injections.\n* Age \\>18 and \\\u003C85 years and able to provide self-consent.\n* Taking five or more prescription drugs at the time of enrollment, of any type.\n* Meets at least one of the following criteria:\n\n  * Elevated 10-year ASCVD risk score ≥7.5% (based on the ACC\u002FAHA ASCVD Risk Estimator Plus tool).\n  * Evidence of subclinical atherosclerosis including:\n\nCalcification in any vascular bed, including coronary arteries and aorta. Calcification of cardiac valves. Breast calcification. Carotid plaque that is not hemodynamically significant.\n\no Type II diabetes on a stable medical regimen with HbA1c \\\u003C8.5%. Per American Diabetes Association guidelines, patients with Type II diabetes aged 40-75 years should be on a moderate-intensity statin.\n\nPatients with documented partial or complete statin intolerance are eligible for enrollment.\n\n* On maximally tolerated statin therapy (which can be no statin for patients with documented intolerance) and have suboptimal LDL levels:\n\n  * For patients with Type II diabetes: LDL \\>70 mg\u002FdL or non-HDL \\>120 mg\u002FdL.\n  * For other patients: LDL \\>90 mg\u002FdL or non-HDL \\>120 mg\u002FdL.\n* Willing to adhere to the randomized study regimen, including subcutaneous injection of inclisiran.\n* Agreement to adhere to lifestyle considerations (see Section 5.3) throughout the study duration.\n\nExclusion Criteria:\n\n* Prior or current use of inclisiran.\n* Known hypersensitivity or allergy to inclisiran or its components.\n* Active liver disease or unexplained persistent elevations in liver enzymes (ALT or AST \\>3x upper limit of normal).\n* History of rhabdomyolysis or severe muscle-related statin intolerance.\n* Uncontrolled diabetes (HbA1c \\>8.5%).\n* Active malignancy requiring systemic therapy.\n* Recent major cardiovascular event (myocardial infarction, stroke, or hospitalization for unstable angina) within the past 3 months.\n* History of organ transplant other than solid-organ transplant.\n* Pregnancy or breastfeeding.\n* Any condition that, in the opinion of the investigator, would make participation unsafe or interfere with study procedures.","ALL","18 Years","85 Years",{"count":21,"type":22},100,"ESTIMATED","INTERVENTIONAL",[25],"PHASE4","Drug-drug interactions often limit statin optimization in a population of patients prescribed cytochrome P3A4 inhibitors, which include immunosuppressive agents, protease inhibitors, and antifungals. These patients frequently have autoimmune conditions or rheumatologic disorders that require complex drug regimens and are often on low-dose statin therapy or no statin at all, resulting in suboptimal LDL levels despite increased cardiovascular (CV) risk.\n\nThere is an unmet clinical need to improve LDL levels in this vulnerable patient population, which faces increased CV risk due to underlying conditions that also contribute to polypharmacy and multiple drug-drug interactions. This study is a randomized, open-label trial evaluating subcutaneous inclisiran plus standard of care for LDL-C lowering in high-risk primary prevention patients with multiple comorbidities (e.g., Type II diabetes, liver disease, chronic kidney disease, autoimmune disease, solid-organ transplant) who are taking five or more medications in which drug-drug interactions prevent optimization of statin therapy.",[28,29,30,31],"Drug Interactions","Primary Prevention","Cardiometabolic Syndrome","LDL-Cholersterol Lowering",[33,34,35,36,37,38],"Statin intolerance","drug drug interaction","inclisiran","LDL-Cholesterol","polypharmacy","multiple comorbidities","RECRUITING","2026-07-10",{"date":42,"type":43},"2026-07-13","ACTUAL",{"date":45,"type":43},"2025-04-02",{"date":47,"type":22},"2027-03-31",{"name":49,"class":50},"University of California, San Diego","OTHER",1,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":56,"acronym":4,"eligibilityCriteria":57,"healthyVolunteers":58,"sex":17,"minAge":18,"maxAge":59,"enrollmentInfo":60,"targetDuration":4,"studyType":23,"phases":62,"briefSummary":64,"conditions":65,"keywords":67,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":51},"100506928","impact-of-yo-yo-sleep-on-cardiometabolic-health-100506928","NCT05880758","Impact of Yo-Yo Sleep on Cardiometabolic Health","Inclusion Criteria:\n\n* Aged 18 to 49 years\n* BMI 20-29.9 kg\u002Fm2\n* Habitually sleeping 7-9 hours\u002Fnight without sleep aids or naps\n\nExclusion Criteria:\n\n* Sleep disorders\n* Psychiatric disorders (including eating disorders) and seasonal affective disorder\n* Pregnancy (current\u002Fprior year)\n* Breastfeeding\n* Smokers (Any cigarette smoking or ex-smokers \\\u003C3years)\n* Diabetes\n* Elevated blood pressure, taking beta-blockers\n* Individuals taking anti-coagulants or anti-platelets\n* Recent weight change or participation in a weight loss program or have ever had bariatric surgery or other weight loss or gastrointestinal procedure.\n* Travel across time zones; shift work (non-traditional hours)",true,"49 Years",{"count":61,"type":22},72,[63],"NA","The goal of this clinical trial is to test the impact of repeated intermittent short sleep, with short sleep maintained 5 days per week followed by 2 days of prolonged sleep, compared to daily adequate sleep, on energy balance and cardiometabolic risk. A secondary goal of this research is to determine if maintaining a constant midpoint of sleep while undergoing intermittent short sleep, leads to better outcomes than intermittent short sleep with a 2-hour delay in sleep midpoint. The aims of this research will be tested in the context of a 3-group, parallel-arm, outpatient intervention of 4 weeks in duration, in young-to-middle-aged adults (aged 18-49 years).",[30,66],"Obesity",[68,69,70],"Sleep","Circadian Rhythms","Cardiometabolic Health","2026-05-14",{"date":73,"type":43},"2026-05-18",{"date":75,"type":43},"2023-09-22",{"date":77,"type":22},"2028-06",{"name":79,"class":50},"Columbia University",{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":4,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":87,"minAge":4,"maxAge":4,"enrollmentInfo":88,"targetDuration":4,"studyType":23,"phases":90,"briefSummary":91,"conditions":92,"keywords":95,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":51},"100537425","the-mom-and-infant-outcomes-momi-study-100537425","NCT06277661","The Mom and Infant Outcomes (MOMI) Study","The Mom and Infant Outcomes (MOMI) Study: A Trial of Perinatal Outpatient Delivery Systems","Inclusion Criteria:\n\nTo be eligible for the MOMI PODS RCT, individuals will be required to be pregnant, with a current diagnosis or history of one or more of the following reflected in the medical record or by self-report - chronic hypertension (with or without super-imposed preeclampsia); gestational hypertension; preeclampsia; eclampsia; hemolysis, elevated liver enzymes and low platelets (HELLP) syndrome; type 1 diabetes mellitus; type 2 diabetes mellitus; gestational diabetes mellitus (GDM); a depressive disorder (e.g., major depressive disorder, persistent depressive disorder) or anxiety disorder (e.g., generalized anxiety disorder, panic disorder).43-48 Inclusion criteria will also include a singleton pregnancy and medical record documentation or self-report of private or government-sponsored health insurance at the time of enrollment.\n\nExclusion Criteria:\n\nExclusion criteria will include the presence of a pre-existing, community driven MOMI PODS referral and enrollment into the program, maternal history of a seizure disorder, medical record documentation or self-report of a major complication of the infant that would be expected to preclude them from receiving or significantly delay their ability to receive outpatient pediatric care during the first year of life. Examples include but are not limited to anencephaly, myelomeningocele, esophageal atresia, gastroschisis, hypoplastic left heart syndrome, transposition of the great arteries, or tetralogy of Fallot. Exclusion criteria will also include the presence of a major genetic disorder among the infant that would be expected to preclude them from receiving or significantly delay their ability to receive outpatient pediatric care during the first year of life. Examples include but are not limited to trisomy 13, or trisomy 18 (trisomy 21 is not an exclusion criteria).","FEMALE",{"count":89,"type":22},384,[63],"The investigator's long-term goal is to mitigate pregnancy-related mortality (PRM) risk by systematically delivering scalable integrated clinical and supportive care that is effective for all. The investigator's central hypothesis is that the Multi-modal Maternal Infant Perinatal Outpatient Delivery System (MOMI PODS) will mitigate postpartum (PP) risk for all by increasing patient engagement with evidence-based cilnical and supportive care, thus improving biopsychosocial profiles that drive clinical risk. To test this hypothesis, the investigators will conduct a hybrid type 1 randomized controlled trial (RCT) of MOMI PODS versus enhanced usual care (EUC, which we will term MOMI CARE) among a total sample of up to 384 mother-infant dyads (192\u002Fgroup) following pregnancy affected by a cardiometabolic and\u002For mental health condition. The investigators will enroll participants during late pregnancy and collect data at baseline and 6 months and 1 year PP. The investigators will collect implementation and service data across sites.",[93,94,30],"Postpartum Depression","Postpartum Anxiety",[96,97,70,98],"Postpartum","Mental Health","Maternal-Infant Health","2026-05-12",{"date":71,"type":43},{"date":102,"type":43},"2024-06-27",{"date":104,"type":22},"2028-03-01",{"name":106,"class":50},"Ohio State University",{"id":108,"slug":109,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":4,"eligibilityCriteria":113,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":114,"enrollmentInfo":115,"targetDuration":4,"studyType":23,"phases":117,"briefSummary":118,"conditions":119,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":130},"100516374","spinal-cord-injury-model-systems-scims---education-module-100516374","NCT06003686","Spinal Cord Injury Model Systems (SCIMS) - Education Module","A Spinal Cord Injury (SCI) Stakeholder-vetted Education Module to Mitigate Early Cardioendocrine Health Risks Occurring After Spinal Cord Injuries.","Inclusion Criteria:\n\n1. Men and Women with SCI\u002FD aged 18-70 years.\n2. Neurologically complete and incomplete American Spinal Injury Association (ASIA) Impairment scale (AIS) A-D spinal cord levels C5 and below.\n3. Enrolled no later than 4 months following discharge from initial rehabilitation from SCI.\n\nExclusion Criteria:\n\n1. Pregnancy determined by urine testing in sexually active females.\n2. Cognitive impairment that compromises the legitimacy of consent.\n3. Grade 3-4 pressure injury at the time of study entry.\n4. Prisoners","70 Years",{"count":116,"type":22},250,[63],"The purpose of this study is to find out if receiving education regarding increased risks of cardiometabolic disease helps subjects understand these risks and how these risks participants' health.",[120,66,30],"Spinal Cord Injuries","2026-04-16",{"date":123,"type":43},"2026-04-20",{"date":125,"type":43},"2024-03-05",{"date":127,"type":22},"2026-10-31",{"name":129,"class":50},"University of Miami",3,{"id":132,"slug":133,"hasResults":11,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":4,"eligibilityCriteria":137,"healthyVolunteers":58,"sex":17,"minAge":18,"maxAge":138,"enrollmentInfo":139,"targetDuration":4,"studyType":23,"phases":141,"briefSummary":142,"conditions":143,"keywords":4,"overallStatus":144,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":4},"100634608","effects-of-berberine-on-cardiometabolic-outcomes-100634608","NCT07541898","Effects of Berberine on Cardiometabolic Outcomes","Effects of Berberine Supplementation on Cardiometabolic Parameters","Inclusion Criteria:\n\n* Healthy\n* Between 18 \\& 65 years\n* Non-smoker\n* BMI \\\u003C 30\n* Able to give informed consent\n\nExclusion Criteria:\n\n* Pregnancy\n* Diabetes or any other metabolic\u002F uncontrolled hypertensive conditions\n* Food allergies to berberine\n* Habitual consumption of berberine\n* Not regularly taking medication or antioxidant supplements","65 Years",{"count":140,"type":22},40,[63],"Cardiovascular disease, type 2 diabetes mellitus and associated diseases combined are the leading health burden and cause of mortality worldwide; therefore, the necessity for an intervention is paramount. Dietary interventions to improve cardiometabolic health are highly sought after as they possess less risk than pharmacological drugs. It has been postulated that Berberine may be beneficial in improving cardiometabolic outcomes. However, to date, no research has explored this using a placebo randomized intervention.",[30],"NOT_YET_RECRUITING","2026-04-14",{"date":147,"type":43},"2026-04-21",{"date":149,"type":22},"2026-07-01",{"date":151,"type":22},"2029-01-01",{"name":153,"class":50},"University of Central Lancashire",{"id":155,"slug":156,"hasResults":11,"nctId":157,"briefTitle":158,"officialTitle":159,"acronym":4,"eligibilityCriteria":160,"healthyVolunteers":58,"sex":17,"minAge":18,"maxAge":138,"enrollmentInfo":161,"targetDuration":4,"studyType":23,"phases":162,"briefSummary":163,"conditions":164,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":51},"100533825","effects-of-quercetin-on-cardiometabolic-outcomes-100533825","NCT06230861","Effects of Quercetin on Cardiometabolic Outcomes","Effects of Quercetin Supplementation on Cardiometabolic Parameters","Inclusion Criteria:\n\n* Healthy\n* Between 18 \\& 65 years\n* Non-smoker\n* BMI \\\u003C 30\n* Able to give informed consent\n\nExclusion Criteria:\n\n* Pregnancy\n* Diabetes or any other metabolic\u002F uncontrolled hypertensive conditions\n* Food allergies to quercetin\n* Habitual consumption of quercetin\n* Not regularly taking medication or antioxidant supplements",{"count":140,"type":22},[63],"Cardiovascular disease, type 2 diabetes mellitus and associated diseases combined are the leading health burden and cause of mortality worldwide; therefore, the necessity for an intervention is paramount. Dietary interventions to improve cardiometabolic health are highly sought after as they possess less risk than pharmacological drugs. It has been postulated that Quercetin may be beneficial in improving cardiometabolic outcomes. However, to date, no research has explored this using a placebo randomized intervention.",[30],"2026-02-25",{"date":167,"type":43},"2026-02-27",{"date":169,"type":43},"2024-03-01",{"date":171,"type":22},"2026-12-01",{"name":153,"class":50},{"id":174,"slug":175,"hasResults":11,"nctId":176,"briefTitle":177,"officialTitle":178,"acronym":179,"eligibilityCriteria":180,"healthyVolunteers":58,"sex":17,"minAge":181,"maxAge":4,"enrollmentInfo":182,"targetDuration":4,"studyType":183,"phases":4,"briefSummary":184,"conditions":185,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":188,"startDateStruct":190,"completionDateStruct":192,"leadSponsor":194,"locationsCount":51},"100576350","the-role-of-ectopic-fat-and-heart-attack-risk-in-hiv-100576350","NCT06784154","The Role of Ectopic Fat and Heart Attack Risk in HIV","The Association of Ectopic Fat and Cardiovascular Disease in People Living With HIV and General Populations: A Cross Sectional Analysis","BHIVA","Inclusion Criteria:\n\n* • \\>40 years\n\n  * HIV-positive\n  * Stable ART for \\>6 months with two VL \\\u003C40 copies\u002Fml based on local testing protocols\n  * CD4 count \\>200cells\u002Fmm3 for \\>2 years from recruitment Inclusion Criteria (all)\n  * Understand the study procedures, able to comply with study procedures and voluntarily agree to participate by giving informed written consent\n\nExclusion Criteria:\n\n* Subjects unable to comply with the study protocol\n* History of severe renal impairment (eGFR \\\u003C30ml\u002Fmin)\n* History of severe hepatic impairment (Child Pugh Score \\>9)\n* Active hepatitis B or hepatitis C\n* Any active illness, which in the opinion of the investigator precludes participation in the study.\n* History of cancer\n* Active illicit intravenous drug use\n* Investigators may decide the subject cannot proceed if there are any relevant other abnormal results in screening assessments\n* History or current GLP-1 agonist use\n* For female subjects: pregnancy or breast feeding at screening.\n* Subjects currently taking: Atypical antipsychotics, omega 3 supplements, Telmisartan\u002FIrbesartan, Thiazolidinediones or regular NSAID use.\n* Familial hypercholesterolaemia","40 Years",{"count":21,"type":22},"OBSERVATIONAL","This study is designed to investigate differences between people living with HIV (PLWHIV) and general populations on how the body utilises and stores energy. This study uses magnetic resonance imaging (MRI) to measure fat around the body organs including the heart and liver. The fat around body organs, also known as visceral fat, is known to be associated with metabolic syndrome and a risk factor for developing heart attacks and strokes.\n\nMRI scans are used frequently in hospitals to diagnose a range of conditions. These scans use radio waves to measure protons in body tissues. The machines can reconstruct tissues using complex algorithms to form composite images of body structures. MRI scans do not use ionising radiation and there is no risk to undertaking an MRI in terms of radiation.\n\nWe often use MRI scans to assess the hearts' structure and function. In addition, we can use specific MRI sequences to assess the integrity of heart muscle. Heart MRI is often considered the gold standard imaging technique to assess the heart and heart muscle disease. This sub-study will use multiple MRI sequences to assess the heart and the liver. We are aiming to investigate any changes in heart and liver fat. In addition, we will assess any changes in fat levels within the heart muscle cells whilst also assessing for any change in the way the heart is functioning.\n\nPLWHIV have roughly double the risk of heart attacks compared to general populations. Previous studies have demonstrated that this increased risk may arise from the way in which fat is stored and metabolised in the body. We hope this study will give insight into why HIV-positive individuals have increased risks of heart attacks and how reducing visceral fat may reduce risk. It may lead to further medicines or treatment strategies to reduce the risk of heart attacks in HIV-positive individuals.",[30,186],"Hiv","2026-02-17",{"date":189,"type":43},"2026-02-19",{"date":191,"type":43},"2024-08-01",{"date":193,"type":22},"2027-06-30",{"name":195,"class":50},"University of Liverpool",{"id":197,"slug":198,"hasResults":11,"nctId":199,"briefTitle":200,"officialTitle":201,"acronym":4,"eligibilityCriteria":202,"healthyVolunteers":11,"sex":87,"minAge":18,"maxAge":4,"enrollmentInfo":203,"targetDuration":4,"studyType":23,"phases":204,"briefSummary":205,"conditions":206,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":208,"lastUpdatePostDateStruct":209,"startDateStruct":211,"completionDateStruct":213,"leadSponsor":215,"locationsCount":51},"100571095","feast-perinatal-support-program-intervention-100571095","NCT06715787","FEAST Perinatal Support Program Intervention","Evaluating the Food Education Access Support Together (FEAST) Perinatal Support Program: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Currently pregnant\n* Speak and read English\n* Eligible for Electronics Benefit Transfer (EBT) and\u002For Women, Infants, and Children (WIC) benefits\n\nExclusion Criteria:\n\n* Inability to attend in-person sessions",{"count":140,"type":22},[63],"Latino individuals face an elevated risk of adverse health outcomes during pregnancy, impacting both the birthing parent and the baby with potential long-term chronic health conditions. While promoting a healthy diet during pregnancy is a promising strategy, interventions targeting dietary behaviors have yielded mixed results and lack widespread dissemination in communities in need. Collaborating with community-based organizations could enhance cultural relevance, build trust with Latino families, and improve program reach and effectiveness. Food Education Access Support Together (FEAST) is a community-based program that promotes healthy eating, well-being, and health equity for diverse, under-resourced urban populations in Los Angeles. The newly developed FEAST Perinatal Support Program (PSP) aims to support individuals through pregnancy and postpartum by providing dietary psychoeducation, skill-building, and social support, with an additional component of grocery gift cards to address food access barriers. This study proposes a pilot trial to assess the feasibility and preliminary efficacy of the FEAST PSP in enhancing dietary outcomes, overall health, and socio-cognitive precursors, in pregnant individuals. The study will enroll 40 pregnant adults in a single-arm study who will receive the core PSP with a $15 gift card for healthful fresh food (PSP+giftcard). Pre- and post-intervention assessments will include questionnaires, dietary recalls, physical measurements, and interviews to evaluate program perceptions. Specific aims include evaluating program feasibility and acceptability (i.e., reach, retention, and participant perceptions) and determining preliminary efficacy on changing socio-cognitive and behavioral aspects of diet, self-reported health, and cardiometabolic risk factors. The project aligns with goals of improving health outcomes in Latino families in Southern California and supports FEAST's strategic objectives for improving health and wellness of individuals during pregnancy and throughout the lifespan. The findings will inform program refinement and future NIH grants for rigorous evaluation of the FEAST PSP.",[207,66,30],"Diet, Healthy","2026-01-29",{"date":210,"type":43},"2026-02-02",{"date":212,"type":22},"2026-02",{"date":214,"type":22},"2026-09",{"name":216,"class":50},"University of Southern California",{"id":218,"slug":219,"hasResults":11,"nctId":220,"briefTitle":221,"officialTitle":221,"acronym":4,"eligibilityCriteria":222,"healthyVolunteers":11,"sex":223,"minAge":18,"maxAge":4,"enrollmentInfo":224,"targetDuration":4,"studyType":23,"phases":226,"briefSummary":227,"conditions":228,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":237,"lastUpdatePostDateStruct":238,"startDateStruct":240,"completionDateStruct":242,"leadSponsor":243,"locationsCount":51},"100520320","black-impact-the-mechanisms-underlying-psychosocial-stress-reduction-in-a-cardiovascular-health-intervention-100520320","NCT06055036","Black Impact: The Mechanisms Underlying Psychosocial Stress Reduction in a Cardiovascular Health Intervention","Inclusion Criteria:\n\n* The inclusion criteria are: 1) Black men (self-report); 2) adult age 18 years or older; 3) Life's Essential 8 total average score \\\u003C 80; 4) English speaking; and 5) lives in Metropolitan Columbus, Ohio.\n\nExclusion Criteria:\n\n* healthcare provider-imposed limitations on physical activity.","MALE",{"count":225,"type":22},340,[63],"Lower attainment of cardiovascular health (CVH), indicated by the American Heart Association's Life's Simple 7 (LS7; physical activity, diet, cholesterol, blood pressure, body mass index, smoking, glycemia) and Life's Essential 8 (LE8; LS7+sleep) metrics, is a major contributor to Black men having the shortest life-expectancy of any non-indigenous race\u002Fsex group. Unfortunately, a paucity of literature exists on interventions aimed at improving CVH among Black men. The team of clinician scientists and community partners co-developed a community-based lifestyle intervention titled Black Impact: a 24-week intervention for Black men with less-than-ideal CVH (\\\u003C4 LS7 metrics in the ideal range) with 45 minutes of weekly physical activity, 45 minutes of weekly health education, and engagement with a health coach, group fitness trainer, and community health worker. Single-arm pilot testing of the intervention (n=74) revealed high feasibility, acceptability, and retention and a 0.93 (95% confidence interval: 0.40, 1.46, p\\\u003C0.001) point increase in LS7 score at 24 weeks. Secondary outcomes included improvements in psychosocial stress (i.e., perceived stress, depressive symptoms), patient activation, and social needs. Thus, robustly powered clinical trials are needed to determine the efficacy of Black Impact and to evaluate the underlying interpersonal and molecular pathways by which Black Impact improves psychosocial stress and CVH. Thus, the investigators propose a randomized, wait-list controlled trial of Black Impact. This novel, community-based intervention to provide a scalable model to improve CVH and psychosocial stress at the population level and evaluate the biological underpinnings by which the intervention mitigates cardiovascular disease risk. The proposed study aligns with American Heart Association's commitment to addressing CVH equity through innovative, multi-modal solutions.",[30,229,230,231,232,66,233,234,68,235,207,236],"Physical Inactivity","Hypertension","Type 2 Diabetes","PreDiabetes","Cardiovascular Diseases","Smoking","Hyperlipidemias","Blood Pressure","2025-09-30",{"date":239,"type":43},"2025-10-06",{"date":241,"type":43},"2023-08-24",{"date":47,"type":22},{"name":106,"class":50},{"id":245,"slug":246,"hasResults":11,"nctId":247,"briefTitle":248,"officialTitle":248,"acronym":4,"eligibilityCriteria":249,"healthyVolunteers":58,"sex":87,"minAge":250,"maxAge":114,"enrollmentInfo":251,"targetDuration":4,"studyType":23,"phases":253,"briefSummary":254,"conditions":255,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":257,"lastUpdatePostDateStruct":258,"startDateStruct":260,"completionDateStruct":262,"leadSponsor":264,"locationsCount":51},"100552723","the-influence-of-chardonnay-marc-intake-on-gut-and-cardiometabolic-health-100552723","NCT06476795","The Influence of Chardonnay Marc Intake on Gut and Cardiometabolic Health","Inclusion Criteria:\n\n* Postmenopausal female, with a cessation of menses for at least 2 years\n* 45-70 years of age\n* BMI 25- 49.9 kg\u002Fm2\n* Fasting triglycerides \\> 120 mg\u002FdL\n* Subject is willing and able to comply with the study protocols and procedures.\n\nExclusion Criteria:\n\n* Self-reported use of daily anticoagulation agents including aspirin, NSAIDs\n* Prescription medications and supplements, except for a 6 month stable dose of thyroid medications\n* Vegan, Vegetarians, food faddists or those consuming a non-traditional diet\n* Fruit consumption ≥ 3 cups\u002Fday\n* Vegetable consumption ≥ 4 cups\u002Fday\n* Coffee\u002Ftea ≥ 3 cups\u002Fday\n* Dark chocolate ≥ 3 oz\u002Fday\n* Self-reported restriction of physical activity due to a chronic health condition\n* Self-reported chronic\u002Froutine high intensity exercise\n* Blood pressure ≥ 140\u002F90 mm Hg\n* Self-reported renal or liver disease\n* Self-reported heart disease, which includes cardiovascular events and stroke, diabetes\n* Peripheral artery disease Raynaud's syndrome or disease\n* Inability to properly place or wear the PAT probes or abnormal measurements on pre-screening PAT\n* Self-reported cancer within past 5 years\n* Self-reported gastrointestinal disorders, apart from appendix removal\n* Unwillingness to stop any supplement use, including herbal, plant or botanical, fish oil, oil supplements six weeks prior to study enrollment.\n* Indications of substance or alcohol abuse within the last 3 years\n* All forms of smoking (e.g. vaping, cigarette, cannabis)\n* Current enrollee in a clinical research study.","45 Years",{"count":252,"type":22},5,[63],"Recently a dietary recommendation of 400 - 600 mg\u002F day has been proposed for the reduced risk of developing cardiovascular disease. Dietary flavanols can be obtained from the intake of foods such as tea, cocoa, wine, berries and apples. Incorporating Chardonnay Marc (the skins and seeds of Chardonnay grapes) into the diet can be an additional source of dietary flavanols. Like other flavanol-rich foods, Chardonnay Marc provides fiber and polysaccharides that may benefit gut health. This study seeks pilot data on the impact of the daily incorporation of Chardonnay Marc powder into the diet on markers of gut and cardiometabolic health.",[233,256,30],"Adiposity","2025-07-07",{"date":259,"type":43},"2025-07-10",{"date":261,"type":43},"2024-06-01",{"date":263,"type":22},"2026-06",{"name":265,"class":50},"University of California, Davis",{"id":267,"slug":268,"hasResults":11,"nctId":269,"briefTitle":270,"officialTitle":271,"acronym":4,"eligibilityCriteria":272,"healthyVolunteers":11,"sex":17,"minAge":273,"maxAge":4,"enrollmentInfo":274,"targetDuration":4,"studyType":23,"phases":276,"briefSummary":277,"conditions":278,"keywords":279,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":287,"lastUpdatePostDateStruct":288,"startDateStruct":290,"completionDateStruct":292,"leadSponsor":294,"locationsCount":51},"100475247","telenutrition-for-individuals-with-sci-100475247","NCT05468437","Telenutrition for Individuals With SCI","Telenutrition to Improve Cardiometabolic Health and Quality of Life Among Individuals With Spinal Cord Injury","Inclusion Criteria:\n\n1. Individuals with traumatic SCI\n2. At least 1-year post-injury\n3. Age 20 years of age or older\n4. BMI \\> 22 kg\u002Fm2 at enrollment\n5. Proficiency in English or Spanish\n6. Living at home or in a private home setting (i.e., not an extended care facility) in the state of California\n7. Able \u002F willing to come to SCVMC for in-person assessments\n8. Primarily a wheelchair user (\\>40 hours per week)\n9. Able to use, or learn how to use, an iPad\n10. Possess adequate decision-making capacity to provide independent informed consent\n\nExclusion Criteria:\n\n1. Medical instability (e.g., uncontrolled hypertension, pneumonia, severe pressure injury)\n2. Current self-reported pregnancy\n3. Other medical condition requiring a strict specialized diet (e.g., renal failure, diabetes)\n4. Participation in another diet program (e.g., Jenny Craig, Weight Watchers, clinic-based program) and\u002For participated in another diet program within the past 6 months\n5. Current or past diagnosis of an eating disorder (e.g., anorexia nervosa, bulimia nervosa, binge eating disorder)\n6. Receiving enteral nutrition\n7. Individuals without a primary care physician\n8. HbA1c \\>7% (these individuals would need to be treated with metformin or other anti-diabetic medication and the intervention would have to be significantly altered for them)\n9. Individuals who are in law enforcement custody","20 Years",{"count":275,"type":22},96,[63],"This study will provide nutrition counseling via FaceTime on an iPad to persons with traumatic spinal cord injury (SCI) who are overweight or obese and are at least one-year post-injury. Nutrition counseling may help participants to develop eating behaviors that match the participants' needs and help improve heart health. The purpose of this project is to decrease the risk of complications like obesity, high cholesterol, or diabetes, and explore associations between bowel and bladder function and nutrition. This study will require 3 in person visits that are about 3 months apart. The total length of the study is about 6 months and includes 3 months of telenutrition counseling.",[120,66,30],[280,66,281,282,283,284,285,286],"Spinal Cord injury","Cardiometabolic","cardiovascular","bowel","bladder","nutrition","telehealth","2025-05-13",{"date":289,"type":43},"2025-05-16",{"date":291,"type":43},"2022-06-13",{"date":293,"type":22},"2026-09-30",{"name":295,"class":50},"Santa Clara Valley Health & Hospital System",{"id":297,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":298,"targetDuration":4,"studyType":23,"phases":299,"briefSummary":26,"conditions":300,"keywords":301,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":302,"lastUpdatePostDateStruct":303,"startDateStruct":305,"completionDateStruct":307,"leadSponsor":309,"locationsCount":51},"100582636",{"count":21,"type":22},[25],[28,29,30,31],[33,34,35,36,37,38],"2025-04-08",{"date":304,"type":43},"2025-04-11",{"date":306,"type":43},"2025-04-03",{"date":308,"type":22},"2026-12-31",{"name":49,"class":50},{"id":311,"slug":312,"hasResults":11,"nctId":313,"briefTitle":314,"officialTitle":315,"acronym":4,"eligibilityCriteria":160,"healthyVolunteers":58,"sex":17,"minAge":18,"maxAge":138,"enrollmentInfo":316,"targetDuration":4,"studyType":23,"phases":317,"briefSummary":318,"conditions":319,"keywords":4,"overallStatus":144,"whyStopped":4,"lastUpdateSubmitDate":320,"lastUpdatePostDateStruct":321,"startDateStruct":323,"completionDateStruct":325,"leadSponsor":327,"locationsCount":51},"100577218","effects-of-green-tea-on-cardiometabolic-outcomes-100577218","NCT06795438","Effects of Green Tea on Cardiometabolic Outcomes","Effects of Green Tea Supplementation on Cardiometabolic Parameters",{"count":140,"type":22},[63],"Cardiovascular disease, type 2 diabetes mellitus and associated diseases combined are the leading health burden and cause of mortality worldwide; therefore, the necessity for an intervention is paramount. Dietary interventions to improve cardiometabolic health are highly sought after as they possess less risk than pharmacological drugs. It has been postulated that Green tea may be beneficial in improving cardiometabolic outcomes. However, to date, no research has explored this using a placebo randomized intervention.",[30],"2025-03-24",{"date":322,"type":43},"2025-03-27",{"date":324,"type":22},"2025-04-01",{"date":326,"type":22},"2027-06-01",{"name":153,"class":50},{"id":329,"slug":330,"hasResults":11,"nctId":331,"briefTitle":332,"officialTitle":333,"acronym":334,"eligibilityCriteria":335,"healthyVolunteers":58,"sex":17,"minAge":18,"maxAge":250,"enrollmentInfo":336,"targetDuration":4,"studyType":23,"phases":338,"briefSummary":339,"conditions":340,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":347,"lastUpdatePostDateStruct":348,"startDateStruct":350,"completionDateStruct":352,"leadSponsor":354,"locationsCount":51},"100511760","circadian-intervention-to-improve-cardiometabolic-health-100511760","NCT05943626","Circadian Intervention to Improve Cardiometabolic Health","Timing of Circadian Synchronizers: the TOCS Study","TOCS","Inclusion Criteria:\n\n1. Age: 18-45 years old; equal numbers of men and women\n2. Body mass index (BMI): 25.0-34.9 kg\u002Fm2,\n3. Sleep Habits: habitual self-reported average total sleep time (TST) \\\u003C6.5 hours per night for prior 6 months\n\nExclusion Criteria:\n\n1. Clinically diagnosed sleep disorder or major psychiatric illness\n2. Evidence of significant organ dysfunction or disease (e.g., diagnosed diabetes, cardiovascular disease, or kidney disease)\n3. Use of prescription drugs or substances known to influence sleep or glucose metabolism\n4. Shift-work: current or history of within last year\n5. Weight change: \\>10% of body weight over prior six months\n6. Experiencing menopause or post-menopausal\n7. Current enrollment in weight loss or physical activity program like the Diabetes Prevention Program\n8. Currently pregnant or planning to become pregnant, or currently lactating.\n9. Currently smoking\n10. Alcohol intake \\>3 drinks per day or \\>14 drinks per week",{"count":337,"type":22},20,[63],"The overall goal is to examine the efficacy of a circadian intervention in people with overweight and obesity and habitual short sleep duration (HSSD). Participants will undergo a randomized controlled trial, with circadian intervention and control (healthy lifestyle) groups. The circadian intervention is designed to reduce nighttime light exposure and after-dinner snack food intake. Alternatively, the control group will receive basic health information (e.g., physical activity, goal setting, and nutrition when eating out).",[30,231,68,341,342,343,344,345,346],"Time Restricted Feeding","Lifestyle Factors","Overweight and Obesity","Insulin Sensitivity","Eating Habit","Sleep Hygiene","2024-12-18",{"date":349,"type":43},"2024-12-20",{"date":351,"type":43},"2023-06-13",{"date":353,"type":22},"2026-03",{"name":355,"class":50},"University of Utah",{"id":357,"slug":358,"hasResults":11,"nctId":359,"briefTitle":360,"officialTitle":360,"acronym":361,"eligibilityCriteria":362,"healthyVolunteers":58,"sex":17,"minAge":363,"maxAge":364,"enrollmentInfo":365,"targetDuration":4,"studyType":23,"phases":367,"briefSummary":369,"conditions":370,"keywords":374,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":381,"lastUpdatePostDateStruct":382,"startDateStruct":384,"completionDateStruct":386,"leadSponsor":388,"locationsCount":51},"100565708","phase-2-hyperpolarized-mr-imaging-with-carbon-13-pyruvate-in-the-human-body-100565708","NCT06645691","Hyperpolarized MR Imaging with Carbon-13 Pyruvate in the Human Body","POLARIC-13","Inclusion Criteria:\n\nHealthy Volunteers:\n\n1. Age 21 years and above\n2. No significant medical co-morbidities (such as chronic kidney disease, diabetes mellitus, heart failure, ischemic heart disease, previous strokes)\n3. No history of cancer\n4. Able and willing to comply with study procedures and provide signed informed consent\n\nPatients with cardiovascular\u002Fcardiometabolic diseases:\n\n1. Age 21 years and above\n2. Physician diagnosed cardiovascular conditions: ischemic heart disease, inherited cardiomyopathies (hypertrophic, dilated or infiltrative cardiomyopathies) and stable heart failure; and\u002For\n3. Cardiometabolic conditions (such as diabetes on medications, hypertension, central obesity, fatty liver disease)\n4. Able and willing to comply with study procedures and provide signed informed consent\n\nExclusion Criteria:\n\n1. Standard contraindications for magnetic resonance procedures (such as implantable medical devices, suspected presence of surgical apparatus or shrapnel, severe claustrophobia)\n2. Unstable medical conditions (such as symptomatic heart failure, unstable hypertension\u002Fglucose levels as determined by investigators, symptomatic arrhythmias, angina)\n3. Pregnant or nursing women\n4. Known allergies to pyruvate or any of its components","21 Years","99 Years",{"count":366,"type":22},200,[368],"PHASE2","Positron emission tomography with 18F fluorodeoxyglucose (FDG) is the conventional imaging technique to provide information regarding tissue glucose uptake and has been highly clinically successful. However, it cannot assess downstream metabolism, which may be useful in the diagnosis and assessment of treatment response in a variety of diseases. Patients will also be exposed to ionizing radiation, the amount of exposure can vary depending on the dose of tracer administered, frequency of scans and duration of each scan. Carbon-13 (13C) magnetic resonance imaging (MRI) is particularly attractive for metabolic imaging because carbon serves as the backbone of nearly all organic molecules in the body. With this technique, the polarization increases to approximately 30%-40%, an increase of over 10,000 to 100,000-fold, thereby dramatically increasing the MRI signal . Whilst the role of 13C imaging has been demonstrated in many sites around the world, we aim to demonstrate the feasibility and application of 13C hyperpolarized imaging in healthy Singapore residents and patients with cardiovascular and\u002For cardiometabolic diseases.",[371,30,372,233,373],"Heart Failure","Cancer Diagnosis","Healthy Volunteers",[375,376,377,378,379,380],"Carbon-13 Pyruvate","Magnetic Resonance Imaging","Lactate","Alanine","Bicarbonate","Hyperpolarized Pyruvate (13C) Injection","2024-12-03",{"date":383,"type":43},"2024-12-06",{"date":385,"type":43},"2024-10-17",{"date":387,"type":22},"2028-05-31",{"name":389,"class":50},"National Heart Centre Singapore",{"id":391,"slug":392,"hasResults":11,"nctId":393,"briefTitle":394,"officialTitle":395,"acronym":4,"eligibilityCriteria":396,"healthyVolunteers":11,"sex":87,"minAge":397,"maxAge":398,"enrollmentInfo":399,"targetDuration":4,"studyType":23,"phases":401,"briefSummary":402,"conditions":403,"keywords":406,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":416,"lastUpdatePostDateStruct":417,"startDateStruct":419,"completionDateStruct":421,"leadSponsor":423,"locationsCount":425},"100557484","interval-training-and-cardio-metabolic-health-in-overweightobese-girls-100557484","NCT06538714","Interval Training and Cardio-metabolic Health in Overweight\u002FObese Girls","Impact of Different Interval Training Protocols on Physical, Cardio-metabolic, Lipidomic, Hematological and Psychological Parameters in Young Overweight\u002FObese Girls","Inclusion Criteria:\n\n* Female gender,\n* Overweight or obese according to the BMI classification,\n* Age, 12 to 15 years,\n* Personal or parental\u002Fguardian written consent\n\nExclusion Criteria:\n\n* Severe infectious or inflammatory diseases,\n* Irregular menstrual cycles\n* Participation in organized exercise training in the last 6 months or additional physical -\n* recreational activities, except physical education classes.\n* Using medications, hormone therapy or dietary supplements","12 Years","15 Years",{"count":400,"type":22},45,[63],"The main purpose of this study is to compare the impact of 12-week moderate-intensity interval training (MIIT) versus combined MIIT with high-intensity interval training (HIIT) on physical fitness, cardio metabolic, lipidomic, hematological and psychological characteristics in young overweight\u002Fobese girls.",[404,405,30,66],"Exercise Overtraining","Enjoyment",[407,408,409,410,411,412,413,414,415],"interval training","obesity","overweight","childhood","cardiometabolic risk","enjoyement","lipidomics","body composition","physical fitness","2024-07-31",{"date":418,"type":43},"2024-08-06",{"date":420,"type":43},"2024-05-20",{"date":422,"type":22},"2024-08-19",{"name":424,"class":50},"Association Tunisienne d'Etude & de Recherche sur l'Athérosclérose",2,{"id":427,"slug":428,"hasResults":11,"nctId":429,"briefTitle":430,"officialTitle":431,"acronym":432,"eligibilityCriteria":433,"healthyVolunteers":58,"sex":17,"minAge":18,"maxAge":434,"enrollmentInfo":435,"targetDuration":436,"studyType":183,"phases":4,"briefSummary":437,"conditions":438,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":443,"lastUpdatePostDateStruct":444,"startDateStruct":446,"completionDateStruct":448,"leadSponsor":450,"locationsCount":51},"100544672","ipsc-biobank-of-biomarkers-diversity-in-cardiovascular-disease-100544672","NCT06371937","iPSC Biobank of Biomarkers Diversity in Cardiovascular Disease","Blood Biomarkers From Ethnically Diverse Cardiovascular Patients","INFERENCE","Inclusion Criteria:\n\n* Adult (18 to 80 years of age)\n* Cardiovascular Disease (CVD)\n* Cerebrovascular Disease (CBD)\n* Peripheral Vascular Disease (PVD)\n* Inherited Arrhythmias\n* Cardiomyopathies\n* Congenital Heart Disease (CHD)\n* Aortopathy\n* Hypertension\n* Cardiometabolic Disease (CMD)\n\nExclusion Criteria:\n\n* Younger than 18 years of age.\n* Patients not able to provide consent.","80 Years",{"count":366,"type":22},"10 Years","The Investigators will create a clinical database and a Biobank of stem cells derived from the blood of participants with cardiovascular disease. The Investigators will recruit participants from diverse racial and ethnic backgrounds with equal representation from both sexes. The Investigators expect to create stem cells and analyze the blood for protein biomarkers and genetic causes of cardiovascular disease. The stem cell biobank and clinical data will be a powerful tool for studying cardiovascular disease.",[233,439,440,371,441,442,30],"Arrythmia","Cardiomyopathies","Cerebrovascular Accident","Congenital Heart Disease","2024-05-28",{"date":445,"type":43},"2024-05-29",{"date":447,"type":43},"2024-05-01",{"date":449,"type":22},"2033-06-30",{"name":451,"class":50},"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's",{"id":453,"slug":454,"hasResults":11,"nctId":455,"briefTitle":456,"officialTitle":457,"acronym":458,"eligibilityCriteria":459,"healthyVolunteers":11,"sex":87,"minAge":460,"maxAge":461,"enrollmentInfo":462,"targetDuration":4,"studyType":23,"phases":464,"briefSummary":465,"conditions":466,"keywords":471,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":483,"lastUpdatePostDateStruct":484,"startDateStruct":486,"completionDateStruct":488,"leadSponsor":490,"locationsCount":51},"100541915","metabolic-flexibility-and-autonomic-control-after-muscle-power-vs-metabolic-power-training-in-postmenopausal-oncological-women-the-power-health-study-100541915","NCT06336070","Metabolic Flexibility and Autonomic Control After Muscle Power vs Metabolic Power Training in Postmenopausal Oncological Women: the POWER Health Study","Postmenopausal Oncological Women Exercising for Recover Their Health. Associations and Changes in Metabolic Flexibility and Autonomic Control After Two Training Programs (Muscle Power vs Metabolic Power): the POWER Health Study","POWER Health","Inclusion Criteria:\n\n* Patients diagnosed of relapse free-cancer (RFC) or patients not diagnosed of any cancer at least the last 15 years (CG)\n* Aged between 35 and 75 years\n* Diagnostic of breast cancer (i.e., including ductal carcinoma, invasive carcinoma, triple negative; RFC) or physiological menopause (CG)\n* Not participating in a nutritional\u002Fdietary intervention\n* Not being physically active (i.e., not to be participating in any physical exercise program in the last 3 months, or performing less than 600 metabolic equivalents (METS)\u002Fweek of moderate-vigorous physical activity).\n* To be capable and willing to provide informed consent\n* Not to suffer from any specific condition that may impede testing of the study hypothesis or make it unsafe to engage in the exercise intervention (i.e., determined by the research staff).\n\nExclusion Criteria:\n\n* Medical contraindication for being engaged in an exercise.\n* Additional surgery planned within the intervention\n* Consuming usually betablocker or any drugs alterning nervous system functioning\n* History of another primary invasive cancer (RFC) or suffer a serious chronic illness (CG)\n* To present any of the following cardiac conditions: (i) myocardial infarction or coronary revascularization procedure within prior 3 months, (ii) uncontrolled hypertension (i.e., systolic ≥180 mmHg or diastolic ≥100 mmHg), (iii) uncontrolled arrhythmias (iv) valvular disease clinically significant, (v) decompensated heart failure or (vi) to suffer from known aortic aneurysm.","35 Years","75 Years",{"count":463,"type":22},56,[63],"POWER Health is a randomized clinical trial with a two-arm parallel design whose objectives are 1) to study metabolic flexibility and autonomic function (both capacities that describe cardiovascular health) in a sample of postmenopausal oncological women vs postmenopausal untreated controls (CT); and 2) to analyze the impact of two different 8-week physical exercise supervised interventions: HIIT training vs strength training focused on muscle power, on both cardiovascular capacities in these populations.",[467,30,468,469,470],"Breast Cancer Female","Metabolism Disorder, Lipid","Autonomic Dysfunction","Cardiovascular Diseases in Old Age",[472,473,474,475,377,476,477,478,479,480,481,482],"Metabolic Flexibility","Heart Rate Variability","Muscle Power","Resting metabolic Rate","High Intensity Interval Training","Strength Training","Breast Cancer","Ageing","Menopause","Female","Exercise Training","2024-04-02",{"date":485,"type":43},"2024-04-04",{"date":487,"type":43},"2024-01-01",{"date":489,"type":22},"2028-12-31",{"name":491,"class":50},"University of Valencia"]